Patient Death Halts Phase I Trial For MediGene RA Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Talked up as a potential blockbuster, RhuDex produced positive Phase IIa findings a month earlier.
You may also be interested in...
MediGene’s ‘Airbag’ Equity Deal Provides EndoTAG-1 Partnering Flexibility
Option lets the firm sell up to 25M Euros in new stock to YA Global over three-year period.
MediGene’s ‘Airbag’ Equity Deal Provides EndoTAG-1 Partnering Flexibility
Option lets the firm sell up to 25M Euros in new stock to YA Global over three-year period.
MediGene Oncologic Imparts 30% Survival Advantage In Pancreatic Cancer Phase II
German firm also studies anti-angiogenesis drug in hormone-resistant breast cancer.